Ireland· IE-PA-EU/1/13/842/01-09
Incresync 12.5 mg/30 mg film-coated tablets
A pioglitazone and alogliptin product containing alogliptin (as benzoate) + pioglitazone (as hydrochloride), registered in Ireland by Takeda Pharma A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Pioglitazone and alogliptin is registered in 9 of 19 countries.
Countries holding a registration under ATC A10BD09 (pioglitazone and alogliptin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Pioglitazone and alogliptin · ATC A10BD09
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Alogliptin (as benzoate) + Pioglitazone (as hydrochloride)
- Manufacturer
- Takeda Pharma A/S
- Country
- Ireland (IE)
- ATC code
- A10BD09
- ATC class
- Pioglitazone and alogliptin
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/13/842/01-09
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pioglitazone and alogliptin in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/24b11f19-e52a-454d-9f8e-5df484528662 GET /v1/drugs/24b11f19-e52a-454d-9f8e-5df484528662?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BD",
"A10BD09"
],
"strength": null,
"pa_number": "EU/1/13/842/01-09",
"substances": [
"Alogliptin (as benzoate)",
"Pioglitazone (as hydrochloride)"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "19/09/2013",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about pioglitazone and alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.